HomeEXECUTIVESRNA Disease Diagnostics Appoints John W. Erickson, Jr. President

RNA Disease Diagnostics Appoints John W. Erickson, Jr. President

RNA Disease Diagnostics, Inc., a company developing a best-in-class molecular diagnostics platform for infectious disease detection, announced today the appointment of John W. Erickson, Jr. to the newly created position of President.

John W. Erickson will lead day-to-day operations, reporting directly to RNA Disease Diagnostics co-founder and Executive Chairman, Allan Oberman.

In an executive management career spanning more than three decades, Mr. Erickson has worked with healthcare, life science, and clinical diagnostics businesses ranging from venture capital-backed start-ups to Fortune 50 companies, building out global commercial capabilities, leading marketing and sales teams, delivering operational excellence and profitable growth, while cultivating strong thought leader relationships across multiple specialties.

Erickson joins RNA Disease Diagnosticsfrom his management and strategy consulting firm, Erickson Healthcare Consulting, which he founded in 2017. Previously, he held C-suite and senior executive leadership positions with RapidBio Systems, Johnson & Johnson (LifeScan), Abbott Laboratories, ITC-Nexus Dx, and Bio-Rad Laboratories. Notably, in those roles, Mr. Erickson played a key role in the development and commercialization of over 36 products, which have generated cumulative sales in excess of $4 billion. Mr. Erickson holds a Master of Science Degree in Management, Bachelor of Science degrees in both Chemistry and Biology, and has completed graduate studies in Biochemistry, Toxicology and Endocrinology.

“I am very pleased to have recruited an executive of John’s caliber to this key position,” said Mr. Oberman. “His extensive and demonstrable record of accomplishment in helping to commercialize new diagnostics technologies in particular will be a great asset for RNA Disease Diagnostics going forward. John is exceptionally qualified to help us maximize the development and commercialization of our Antisense RNA diagnostic platform across multiple diseases.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

Don't Miss

Hinge Health Acquires the Most Advanced Computer Vision Technology for Tracking Human Motion

CEO Daniel Perez explained, “We won’t stop investing in technology to deliver the most patient-centered digital clinic that improves member experience and outcomes while reducing costs. wrnch allows us to take a giant leap forward in all respects.”

Dale W Wood Congratulates the Huma Team on Raising $130 Million

Major health and technology companies across the world have committed upwards of $130 million to Huma Therapeutics, the health-tech company backed by Dale Ventures.

Rhaeos Awarded $4 Million NIH SBIR Grant

Under the NIH SBIR grant, Rhaeos will leverage their existing wireless sensor hardware to provide additional quantitative flow data to the clinician, giving insight into this currently inaccessible and highly relevant shunt performance metric.

Gynesonics Announces FDA Clearance of Next Generation Sonata System

“This clearance brings significant system improvements that expand the location of fibroids that can be treated while allowing the physician to control all aspects of the treatment from within the sterile field,” said Jiayu Chen, Ph.D. Vice President, Engineering and Advanced Technologies at Gynesonics.

Blackrock Neurotech Invests In Groundbreaking Auditory Nerve Implant With University Of Minnesota And MED-EL

The new investment will enable the development and translation of a new ANI through preclinical studies and later, a pilot clinical trial, where the ANI is then implanted in up to three deaf patients.

Jonathan Chapman: New President/CEO of Trividia Health

Chapman said, “I’m honored to join the Trividia team as President and CEO. This organization has a long history of leadership within the healthcare industry as a provider of accurate, accessible, and affordable point-of-care solutions for the management of diabetes.”

SOLOPASS® System (Bedside Neuro-Navigation Device) Receives FDA 510(k) Clearance

inTRAvent’s SOLOPASS® system brings simple, portable, bedside neuro-navigation into the intensive care unit.

Skyhawk Therapeutics Completes New Investment Round

A $133 million round of investment will allow Skyhawk to accelerate development of its novel small molecule RNA-modifying drug candidates into the clinic.

By using this website you agree to accept Medical Device News Magazine Privacy Policy